参考文献
［1］Sung H，Ferlay J，Siegel RL，et al.Global Cancer Statistics 2020：GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries［J］.CA：a cancer journal for clinicians，2021，71（3）：209-249.
［2］French SW，Disibio G.Metastatic patterns of cancers：results from a large autopsy study［J］.Archives of Pathology&Laboratory Medicine，2008，132（6）：931.
［3］中国医师协会外科医师分会，中华医学会外科学分会胃肠外科组，中华医学会外科学分会结直肠外科学组，等.中国结直肠癌肝转移诊断和综合治疗指南（2020版）［J］.中国实用外科杂志，2021，41（1）：1-11.
［4］中国研究型医院学会消化道肿瘤专业委员会，中国医师协会外科医师分会上消化道外科医师委员会，中国抗癌协会胃癌专业委员会，等.胃癌肝转移诊断与综合治疗中国专家共识（2019版）［J］.中国实用外科杂志，2019，39（5）：405-411.
［5］Zeng H，Chen W，Zheng R，et al.Changing cancer survival in China during 2003-15：a pooled analysis of 17 population-based cancer registries［J］.Lancet Glob Health，2018，6（5）：e555-e567.
［6］日本国立癌症研究中心.全がん協加盟施設の生存率データの更新にあたって［EB／OL］.（2023-01-05）［2023-08-13］.http：／／www.zengankyo.ncc.go.jp／etc／seizonritsu／seizonritsu2012.html＃10.
［7］中华人民共和国国家卫生健康委员会医政医管局.胃癌诊疗指南（2022年版）［J］.中华消化外科杂志，2022，21（9）：1137-1164.
［8］Bertotti Andrea，Papp Eniko，Jones Siân，et al.The genomic landscape of response to EGFR blockade in colorectal cancer［J］.Nature，2015，526（7572）：263-267.
［9］Mao C，Yang ZY，Hu XF，Chen Q，et al.PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer：a systematic review and meta-analysis［J］.Ann Oncol，2012，23（6）：1518-1525.
［10］Brudvik KW，Kopetz SE，Li L，et al. Meta-analysis of KRAS mutations and survival after resection of colorectal liver metastases［J］.The British Journal of Surgery，2015，102（10）：1175-1183.
［11］Karagkounis G，Torbenson MS，Daniel HD，et al. Incidence and prognostic impact of KRAS and BRAF mutations in patients undergoing liver surgery for colorectal metastases［J］.Journal of Clinical Oncology，2012，30（15＿suppl）：3616.(https://www.daowen.com)
［12］Pierobon M，Ramos C，Wong S，et al.Enrichment of PI3K-AKT-mTOR pathway activation in hepatic metastases from breast cancer［J］.Clin Cancer Res，2017，23（16）：4919-4928.
［13］Angus L，Smid M，Wilting SM，et al.The genomic landscape of metastatic breast cancer highlights changes in mutation and signature frequencies［J］.Nature Genetics，2019，51（10）：1450-1458.
［14］Hsu Fred，De Caluwe b Alex，Anderson David，et al.EGFR mutation status on brain metastases from non-small cell lung cancer［J］.Lung Cancer，2016，96：101-107.
［15］Bang YJ，Van CE，Feyereislova A，et al.Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer（ToGA）：a phase 3，open-label，randomised controlled trial［J］.Lancet，2010，376（9742）：687-697.
［16］Janjigian YY，Maron SB，Chatila WK，et al.First-line pembrolizumab and trastuzumab in HER2-positive oesophageal，gastric，or gastrooesophageal junction cancer：an open-label，single-arm，phase 2 trial［J］.The Lancet Oncology，2020，21（6）：821-831.
［17］Ali SM，Sanford EM，Klempner SJ，et al.Prospective comprehensive genomic profiling of advanced gastric carcinoma cases reveals frequent clinically relevant genomic alterations and new routes for targeted therapies［J］.Oncologist，2015，20（5）：499.
［18］Lee J，Kim ST，Kim K，et al.Tumor gnomic profiling guides patients with metastatic gastric cancer to targeted treatment：the viktory umbrella trial［J］.Cancer discovery，2019，9（10）：1388-1405.
［19］Varghese AM，Arora A，Capanu M，et al.Clinical and molecular characterization of patients with cancer of unknown primary in the modern era［J］.Ann Oncol，2017，28（12）：3015-3021.
［20］Ross JS，Wang K，Gay L，et al.Comprehensive genomic profiling of carcinoma of unknown primary site：new routes to targeted therapies［J］.Jama Oncol，2015，1（1）：40-49.
［21］Priestley P，Baber J，Lolkema MP，et al. Pan-cancer whole-genome analyses of metastatic solid tumours［J］.Nature，2019，575（D1）：210-216.
［22］Hainsworth JD，Meric-Bernstam F，Swanton C，et al. Targeted therapy for advanced solid tumors on the basis of molecular profiles：results from mypathway，an open-label，phaseⅡa multiple basket study［J］.Journal of Clinical Oncology，2018，36（6）：536-542.